A dose-escalation study of RG-7624 for the treatment of inflammation associated with asthma.
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2016
At a glance
- Drugs Afasevikumab (Primary)
- Indications Inflammation
- Focus Adverse reactions
- 10 Oct 2016 New trial record
- 05 Sep 2016 According to a NovImmune SA media release, Genentech dosed the first patient in this study.